Technical Analysis for OVID - Ovid Therapeutics Inc.

Grade Last Price % Change Price Change
F 2.8 1.82% 0.05
OVID closed up 1.82 percent on Tuesday, January 26, 2021, on 2.52 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical OVID trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Doji - Bearish? Reversal 0.00%
Upper Bollinger Band Walk Strength 0.00%
Weak + Overbought Other 0.00%
Weak, Overbought and Reversal Signs Reversal 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Older End-of-Day Signals for OVID ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 19 hours ago
3x Volume Pace about 19 hours ago
Up 5% about 19 hours ago
Possible Pocket Pivot about 19 hours ago
Up 10% about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ovid Therapeutics Inc. Description

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Disorders Symptoms Neurological Disorders Epilepsy Syndromes Takeda Pharmaceutical Company Urological Disorders Genodermatoses Fragile X Syndrome Sedatives Anticonvulsants Rare Neurological Disorders

Is OVID a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.4
52 Week Low 1.8
Average Volume 2,030,226
200-Day Moving Average 5.21
50-Day Moving Average 3.50
20-Day Moving Average 2.50
10-Day Moving Average 2.59
Average True Range 0.21
ADX 26.0
+DI 30.24
-DI 17.29
Chandelier Exit (Long, 3 ATRs ) 2.46
Chandelier Exit (Short, 3 ATRs ) 2.87
Upper Bollinger Band 2.76
Lower Bollinger Band 2.24
Percent B (%b) 1.08
BandWidth 20.62
MACD Line -0.15
MACD Signal Line -0.26
MACD Histogram 0.1142
Fundamentals Value
Market Cap 177.33 Million
Num Shares 63.3 Million
EPS -1.78
Price-to-Earnings (P/E) Ratio -1.57
Price-to-Sales 52.66
Price-to-Book 6.63
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.30
Resistance 3 (R3) 3.33 3.21 3.21
Resistance 2 (R2) 3.21 3.08 3.19 3.18
Resistance 1 (R1) 3.00 3.00 2.97 2.97 3.16
Pivot Point 2.88 2.88 2.86 2.86 2.88
Support 1 (S1) 2.67 2.75 2.64 2.64 2.44
Support 2 (S2) 2.55 2.67 2.53 2.42
Support 3 (S3) 2.34 2.55 2.39
Support 4 (S4) 2.31